Evotec SE filed an 8-K on October 29, 2026, announcing a webcast and conference call scheduled for November 5, 2026, at which the company will present its financial results for the first nine months of 2026 along with a business update.

Key Highlights

  • Event date: The webcast and conference call is scheduled for Thursday, November 5, 2026.
  • Start time: The call begins at 2:00 pm CET (1:00 pm GMT, 8:00 am EST), according to the filing.
  • Coverage period: Management will discuss financial results covering the first nine months of 2026.
  • Language: The conference call will be conducted in English, the filing states.
  • Access: Pre-registration is required for both the audio webcast and the dial-in conference call, with confirmation details sent by email after registration.
  • Listing venues: Evotec SE trades on NASDAQ:EVO and on the Frankfurt Prime Standard under the symbol EVT, as stated in the filing.

Evotec Announces Investor Event for First Nine Months 2026 Results

According to the October 29, 2026 filing, Evotec SE, a life science company that the filing describes as "pioneering the future of drug discovery and development," will host a combined webcast and conference call on November 5, 2026. The event is intended to cover the company's financial results for the first nine months of 2026 as well as a broader business update. Participants can access the event either via an audio webcast with accompanying presentation slides or by dialing in by phone, with a simultaneous slide presentation available for phone participants.

The filing describes Evotec's operations as spanning small molecules, biologics, cell therapies, and associated modalities, supported by proprietary platforms including Molecular Patient Databases, PanOmics, and iPSC-based disease modeling. The company states it works with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Evotec reported a global team of around 4,500 experts operating from sites in Europe and the U.S. The company also noted a portfolio of over 100 proprietary R&D assets, most of them co-owned, with a focus on oncology, cardiovascular and metabolic diseases, neurology, and immunology.

The filing includes forward-looking statements, which the company cautions are "based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made," and are subject to known and unknown risks and uncertainties. Evotec "expressly disclaims any obligations or undertaking to release publicly any updates or revisions" to those statements, according to the filing. Investor relations contact listed is Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations.

What Was Disclosed

Evotec SE disclosed plans for a November 5, 2026 webcast and conference call to present first-nine-months 2026 financial results and a business update. The filing provides registration details for both audio webcast and phone dial-in access, with the event set for 2:00 pm CET.